The stock of Summit Therapeutics Inc (NASDAQ: SMMT) has increased by 0.43 when compared to last closing price of 27.90.Despite this, the company has seen a gain of 16.22% in its stock price over the last five trading days. zacks.com reported 2025-05-02 that SMMT’s first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
The 36-month beta value for SMMT is also noteworthy at -0.95. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SMMT is 111.14M, and at present, short sellers hold a 22.58% of that float. The average trading volume of SMMT on May 06, 2025 was 3.95M shares.
SMMT’s Market Performance
SMMT’s stock has seen a 16.22% increase for the week, with a 48.18% rise in the past month and a 40.24% gain in the past quarter. The volatility ratio for the week is 8.42%, and the volatility levels for the past 30 days are at 14.80% for Summit Therapeutics Inc The simple moving average for the past 20 days is 13.81% for SMMT’s stock, with a 47.14% simple moving average for the past 200 days.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Citigroup repeating the rating for SMMT by listing it as a “Buy.” The predicted price for SMMT in the upcoming period, according to Citigroup is $35 based on the research report published on March 26, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to SMMT, setting the target price at $30 in the report published on March 12th of the current year.
SMMT Trading at 30.50% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.09% of loss for the given period.
Volatility was left at 14.80%, however, over the last 30 days, the volatility rate increased by 8.42%, as shares surge +61.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.67% upper at present.
During the last 5 trading sessions, SMMT rose by +16.22%, which changed the moving average for the period of 200-days by +200.97% in comparison to the 20-day moving average, which settled at $24.62. In addition, Summit Therapeutics Inc saw 57.02% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SMMT
The total capital return value is set at -0.48. Equity return is now at value -123.93, with -85.89 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -26.84. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -30.27.
Currently, EBITDA for the company is -212.85 million with net debt to EBITDA at 1.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.63.
Conclusion
In summary, Summit Therapeutics Inc (SMMT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
